Simplify Logo

Full-Time

Manager/Sr. Manager

Communications

Confirmed live in the last 24 hours

Voyager Therapeutics

Voyager Therapeutics

51-200 employees

Develops genetic medicines for neurological diseases

Hardware
Biotechnology
Healthcare

Mid, Senior

Lexington, MA, USA

Category
Public Health
Biology & Biotech
Requirements
  • Minimum of 3 years of communications experience in the biopharma industry, either in-house at a biopharmaceutical company or at an agency
  • Bachelor's degree required, preferably in science, business, or related field
  • Excellent communication skills, both verbal and written, with the ability to articulate complex concepts clearly and concisely to diverse audiences
  • Ability to thrive in a fast-paced, dynamic environment, with a high level of adaptability, flexibility, and resilience to changing priorities and business needs.
  • Ability to collaborate effectively with cross-functional teams at all levels
  • Strong attention to detail and a commitment to accuracy
  • Ability to work independently and use sound judgement and decision-making skills
  • Candidates will be assessed for the level of the role according to their individual experience and capabilities
Responsibilities
  • Lead all digital and social media efforts; create and/or oversee creation and review of all content.
  • Support corporate communications efforts such as press releases, media outreach, and thought leadership, working with external PR firm.
  • Support investor communications materials such as earnings releases, corporate decks, earnings call materials, etc., working with external IR firm.
  • Own visual brand; lead coordination of cohesive use of logo and visual design elements across all departments and materials.
  • Support evolution of corporate narrative working with Chief Corporate Affairs Officer and brand/design firm.
  • Lead strategy and execution for internal communications, including Town Halls, Leadership Communications, Intranet, Newsletter, TVs, and other events/channels.
  • Own creation of all internal communications content (and/or oversee all content creation with agency partner and internal partners, such as HR team).
  • Support corporate-level patient advocacy, including budget/requests for funding, partnering with clinical/medical teams.

Voyager Therapeutics develops genetic medicines aimed at treating neurological diseases, particularly those affecting the central nervous system like amyotrophic lateral sclerosis (ALS). Their approach involves using a proprietary platform that utilizes adeno-associated virus (AAV) technology to deliver genetic material directly to the brain through intravenous dosing, overcoming the challenge of the blood-brain barrier. Unlike many competitors, Voyager focuses on creating treatments that are specifically designed for neurological conditions, and they emphasize collaboration with larger pharmaceutical companies to enhance their research and development efforts. The company's goal is to provide transformative therapies that significantly improve the lives of patients suffering from severe neurological disorders.

Company Stage

IPO

Total Funding

$344M

Headquarters

Cambridge, Massachusetts

Founded

2014

Growth & Insights
Headcount

6 month growth

7%

1 year growth

28%

2 year growth

47%
Simplify Jobs

Simplify's Take

What believers are saying

  • Voyager's recent $100 million upfront payment from Novartis highlights strong financial backing and potential for rapid growth.
  • The appointment of experienced executives like Nathan Jorgensen as CFO and Toby Ferguson as CMO strengthens the company's leadership team.
  • The selection of a development candidate for the GBA1 program in collaboration with Neurocrine Biosciences demonstrates the productivity and potential of their partnerships.

What critics are saying

  • The highly specialized focus on neurological diseases may limit market opportunities compared to broader biotech firms.
  • Dependence on partnerships and milestone payments introduces financial uncertainty if collaborations do not yield expected results.

What makes Voyager Therapeutics unique

  • Voyager Therapeutics leverages its proprietary AAV capsid discovery platform to deliver genetic material directly to the brain, a significant advancement over traditional methods.
  • The company's focus on crossing the blood-brain barrier addresses a critical challenge in treating neurological diseases, setting it apart from many competitors.
  • Voyager's strong emphasis on collaborative partnerships with major pharmaceutical companies like Novartis accelerates its R&D and commercialization efforts.